GSK 932121

Drug Profile

GSK 932121

Alternative Names: 932121; 932121A; GSK-932121; GSK-932121A

Latest Information Update: 02 Aug 2013

Price : $50

At a glance

  • Originator GlaxoSmithKline; Medicines for Malaria Venture
  • Developer GlaxoSmithKline
  • Class Fluorine compounds; Phenyl ethers; Pyridones; Small molecules
  • Mechanism of Action Electron transport complex I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Malaria

Most Recent Events

  • 02 Aug 2013 No development reported - Phase-I for Malaria in Australia (unspecified route)
  • 15 Apr 2011 GlaxoSmithKline terminates phase I trial in Healthy volunteers in Australia (NCT00811356)
  • 26 Mar 2010 Phase-I clinical trials in Malaria in Australia (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top